GO
Loading...

Pfizer Inc

More

  • Final Glance: Pharmaceuticals companies Friday, 17 Apr 2015 | 6:03 PM ET

    Baxter International Inc. fell$. 24 or. 3 percent, to $69.91. Hospira fell$. 21 or. 2 percent, to $87.46. Johnson& Johnson fell$. 21 or. 2 percent, to $99.58.

  • April 17- Pfizer Inc was cleared of liability on Friday in the first lawsuit to go to trial of more than 1,000 filed across the United States alleging that its antidepressant Zoloft can cause birth defects, a company spokeswoman said. Plaintiff Kristyn Pesante claimed that Pfizer failed to warn that using Zoloft during pregnancy could cause birth defects, and...

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...

  • Most active New York Stock Exchange-traded stocks Friday, 17 Apr 2015 | 1:17 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. AT&T Inc. fell. 7 percent to $32.51 with 29,042,800 shares traded. Alcoa Inc. rose. 1 percent to $13.46 with 23,252,700 shares traded.

  • Midday Glance: Pharmaceuticals companies Friday, 17 Apr 2015 | 1:17 PM ET

    Baxter International Inc. fell$. 23 or. 3 percent, to $69.92. Bristol-Myers Squibb Co. rose $1.84 or 2.9 percent, to $65.52. Eli Lilly& Co. fell$. 97 or 1.3 percent, to $72.52.

  • Early Glance: Pharmaceuticals companies Friday, 17 Apr 2015 | 10:57 AM ET

    Baxter International Inc. fell$. 23 or. 3 percent, to $69.92. Bristol-Myers Squibb Co. rose $1.68 or 2.6 percent, to $65.36. Johnson& Johnson fell$. 23 or. 2 percent, to $99.56.

  • Final Glance: Pharmaceuticals companies Thursday, 16 Apr 2015 | 6:03 PM ET

    Baxter International Inc. fell$. 05 or. 1 percent, to $70.15. Bristol-Myers Squibb Co. rose$. 25 or. 4 percent, to $63.68. Hospira fell$. 02 or percent, to $87.67.

  • Midday Glance: Pharmaceuticals companies Thursday, 16 Apr 2015 | 1:29 PM ET

    Baxter International Inc. fell$. 12 or. 2 percent, to $70.08. Bristol-Myers Squibb Co. rose$. 19 or. 3 percent, to $63.62. Eli Lilly& Co. fell$. 10 or. 1 percent, to $73.61.

  • Final Glance: Pharmaceuticals companies Wednesday, 15 Apr 2015 | 5:57 PM ET

    Baxter International Inc. rose$. 22 or. 3 percent, to $70.20. Bristol-Myers Squibb Co. fell$. 60 or. 9 percent, to $63.43. Eli Lilly& Co. rose$. 25 or. 3 percent, to $73.71.

  • Most active New York Stock Exchange-traded stocks Wednesday, 15 Apr 2015 | 2:34 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. Alcoa Inc. fell. 2 percent to $13.34 with 34,214,000 shares traded. Bank of America Corp. fell 1.1 percent to $15.64 with 115,292,100 shares traded.

  • Midday Glance: Pharmaceuticals companies Wednesday, 15 Apr 2015 | 2:34 PM ET

    Baxter International Inc. rose$. 48 or. 7 percent, to $70.46. Bristol-Myers Squibb Co. fell$. 27 or. 4 percent, to $63.76. Eli Lilly& Co. rose$. 19 or. 3 percent, to $73.65.

  • LONDON, April 15- Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move-- quite literally. Chief Executive Pascal Soriot is making AstraZeneca more nimble as hopes build for its cancer pipeline, but he still has his work cut out to keep 2015 earnings above the floor needed to protect his...

  • Final Glance: Pharmaceuticals companies Tuesday, 14 Apr 2015 | 5:58 PM ET

    Baxter International Inc. rose$. 11 or. 2 percent, to $69.98. Bristol-Myers Squibb Co. rose$. 08 or. 1 percent, to $64.03. Eli Lilly& Co. fell$. 06 or. 1 percent, to $73.46.

  • Midday Glance: Pharmaceuticals companies Tuesday, 14 Apr 2015 | 1:34 PM ET

    Baxter International Inc. rose$. 02 or percent, to $69.89. Bristol-Myers Squibb Co. rose$. 28 or. 4 percent, to $64.23. Hospira rose$. 04 or percent, to $87.68.

  • Early Glance: Pharmaceuticals companies Tuesday, 14 Apr 2015 | 10:42 AM ET

    Baxter International Inc. fell$. 13 or. 2 percent, to $69.74. Bristol-Myers Squibb Co. fell$. 24 or. 4 percent, to $63.71. Eli Lilly& Co. fell$. 27 or. 4 percent, to $73.25.

  • INSIGHT-Banks see talent flee amid healthcare M&A boom Tuesday, 14 Apr 2015 | 1:00 AM ET

    JPMorgan Chase& Co and Bank of America have both lost senior healthcare investment bankers to boutique investment bank Guggenheim Partners, showing that banks face challenges in being able to pay competitive rates. Healthcare has been the busiest sector for deals so far this year, fueled by transactions such as Pfizer Inc's $17 billion offer for Hospira Inc...

  • Demand for newer cancer and multiple sclerosis treatments, price increases on branded medicines, particularly insulin products for diabetes, and the entry of few new generic versions of big-selling drugs also contributed to the double-digit spending rise in 2014, the report by IMS Health Holdings Inc found. "We certainly expect to see growth in the market...

  • Final Glance: Pharmaceuticals companies Monday, 13 Apr 2015 | 6:00 PM ET

    Baxter International Inc. fell$. 70 or 1.0 percent, to $69.87. Bristol-Myers Squibb Co. fell$. 69 or 1.1 percent, to $63.95. Eli Lilly& Co. fell$. 40 or. 5 percent, to $73.52.

  • April 13- Drugmaker Mylan N.V said it settled a patent litigation with Pfizer Inc related to Viagra, paving the way for the launch of the drug's generic version in the United States once approved. Pfizer's patent for Viagra, used to treat erectile dysfunction, expires in 2020.. Pfizer's shares closed down marginally at $35.09, after touching an 11- year high on...

  • Mylan settles Viagra patent litigation with Pfizer Monday, 13 Apr 2015 | 3:33 PM ET

    April 13- Drugmaker Mylan N.V said it settled a patent litigation with Pfizer Inc related to the generic version of Viagra. Mylan said the settlement would allow it to launch a generic version of the drug as early as December 2017, or sooner under certain conditions, subject to approval by U.S. health regulators. Other terms of the settlement were not disclosed.